e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Understanding the impact of the lung microenvironment to enhance the therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome
Claire Masterson, Hector Gonzalez, John G. Laffey
Source:
Eur Respir J, 58 (4) 2100986; 10.1183/13993003.00986-2021
Journal Issue:
October
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Claire Masterson, Hector Gonzalez, John G. Laffey. Understanding the impact of the lung microenvironment to enhance the therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome. Eur Respir J, 58 (4) 2100986; 10.1183/13993003.00986-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Lane-hamilton syndrome and CCF: a fatal association
Late Breaking Abstract - The mortality predicting factors at admission and during hospitalisation of pateints with SARS COV2
Related content which might interest you:
Progress and potential of mesenchymal stromal cell therapy in acute respiratory distress syndrome
Source: Eur Respir Monogr 2021; 91: 353-372
Year: 2021
Effects of hypercapnic acidosis on the primary cells relevant to ARDS pathophysiology and the therapeutic potential of mesenchymal stem cells
Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury
Year: 2017
The therapeutic potential of the mesenchymal stem cell secretome in a mouse model of chronic inflammatory lung disease
Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair
Year: 2019
The new-defined mesenchymal stromal/stem cell marker has a protective role in the development of acute lung injury.
Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling
Year: 2019
Potential effects of the mechanical microenvironment in lung bioengineering with stem cells
Source: Research Seminar 2014 - The many faces of stem cells in respiratory diseases
Year: 2014
Mesenchymal stromal cells (MSC) anti-microbial effect in acute respiratory distress syndrome (ARDS) is mediated in part by enhanced alveolar macrophage phagocytosis through cell contact-dependent mitochondrial transfer leading to improved macrophage bioenergetics
Source: International Congress 2016 – Novel insights into alveolar and bronchial epithelial cell injury and repair
Year: 2016
The role of resident lung mesenchymal stromal cells in normal and aberrant lung development
Source: Virtual Congress 2020 – Cellular involvement in lung injury
Year: 2020
Human mesenchymal stem cell exosomes attenuate inflammation of lung epithelial cells through miR-223 in acute lung injury
Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair
Year: 2019
Mechanical programming of mesenchymal stromal cells to treat lung fibrosis
Source: ERS Lung Science Conference 2018
Year: 2018
Mesenchymal stem cell therapy reduces inflammation and damage in a model of chronic lung disease
Source: ERS Lung Science Conference 2017
Year: 2017
Which is the best source of mesenchymal cells to treat acute lung injury?
Source: Annual Congress 2011 - Mechanisms of acute lung injury and mesenchymal cell treatment
Year: 2011
Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Characterization of human mesenchymal stem cells phenotype and secretome in a in vitro model of acute lung injury inflammation
Source: Annual Congress 2011 - Lung cell injury and repair
Year: 2011
Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis
Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies
Year: 2020
Immunotherapeutic strategy with mesenchymal stem cells modulating inflammation in an experimental model of COPD.
Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD
Year: 2020
The use of alveolar epithelial type I cell-selective markers to investigate lung injury and repair
Source: Eur Respir J 2004; 24 : 664-673
Year: 2004
Protective roles of paracrine factors of bone marrow mesenchymal stem cells in bleomycin induced lung epithelial cell injury in vitro and pulmonary fibrosis in vivo
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury
Source: Eur Respir J 2009; 33: 1403-1414
Year: 2009
Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury
Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020
Year: 2022
Induced pluripotent stem cells for generating lung alveolar epithelial cells and modelling respiratory disease
Source: Eur Respir Monogr 2021; 91: 205-221
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept